Nanoneedles Induce Targeted siRNA Silencing of p16 in the Human Corneal Endothelium.
gene therapy
nanoneedles
porous silicon
regenerative medicine
siRNA
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
08
09
2022
received:
02
06
2022
pubmed:
18
10
2022
medline:
26
11
2022
entrez:
17
10
2022
Statut:
ppublish
Résumé
Nanoneedles can target nucleic acid transfection to primary cells at tissue interfaces with high efficiency and minimal perturbation. The corneal endothelium is an ideal target for nanoneedle-mediated RNA interference therapy aimed at enhancing its proliferative capacity, necessary for tissue regeneration. This work develops a strategy for siRNA nanoninjection to the human corneal endothelium. Nanoneedles can deliver p16-targeting siRNA to primary human corneal endothelial cells in vitro without toxicity. The nanoinjection of siRNA induces p16 silencing and increases cell proliferation, as monitored by ki67 expression. Furthermore, siRNA nanoinjection targeting the human corneal endothelium is nontoxic ex vivo, and silences p16 in transfected cells. These data indicate that nanoinjection can support targeted RNA interference therapy for the treatment of endothelial corneal dysfunction.
Identifiants
pubmed: 36253148
doi: 10.1002/advs.202203257
pmc: PMC9685449
doi:
Substances chimiques
RNA, Small Interfering
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2203257Subventions
Organisme : UKRI-MRC
ID : MC_PC_16048
Organisme : European Research Council
ID : 759577
Pays : International
Informations de copyright
© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH.
Références
Cornea. 2017 Dec;36(12):1576-1579
pubmed: 28902013
Adv Funct Mater. 2010 Jul 23;20(14):2231-2239
pubmed: 21057669
Adv Mater. 2020 Jun;32(24):e2000036
pubmed: 32378244
Cell Transplant. 2015;24(2):287-304
pubmed: 24268186
Transl Vis Sci Technol. 2019 Nov 15;8(6):13
pubmed: 31772824
Nat Commun. 2014 Jul 29;5:4466
pubmed: 25072981
Br J Ophthalmol. 2016 Aug;100(8):1151-6
pubmed: 27226345
Exp Eye Res. 2021 Jan;202:108361
pubmed: 33212142
Mol Vis. 2010 May 25;16:897-906
pubmed: 20508865
Curr Eye Res. 2005 Mar;30(3):213-9
pubmed: 15804747
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1870-5
pubmed: 20080678
Drug Discov Today. 2019 Aug;24(8):1446-1457
pubmed: 30738982
Surv Ophthalmol. 2018 Mar - Apr;63(2):149-165
pubmed: 28782549
J Biol Chem. 2018 Mar 9;293(10):3758-3769
pubmed: 29363574
Acta Biomater. 2012 Mar;8(3):1156-63
pubmed: 21982848
Exp Eye Res. 2012 Feb;95(1):54-9
pubmed: 21777585
Front Genet. 2022 Jan 07;12:794805
pubmed: 35069693
Adv Mater. 2019 Mar;31(12):e1806788
pubmed: 30680803
Nat Mater. 2015 May;14(5):532-9
pubmed: 25822693
Invest Ophthalmol Vis Sci. 2020 Sep 1;61(11):26
pubmed: 32931574
Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1566-75
pubmed: 8675399
Adv Sci (Weinh). 2022 Nov;9(33):e2203257
pubmed: 36253148
Front Med (Lausanne). 2021 Jun 29;8:688223
pubmed: 34268324
JAMA Ophthalmol. 2016 Feb;134(2):167-73
pubmed: 26633035
Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1763-70
pubmed: 15161838
ACS Nano. 2015 May 26;9(5):5500-5509
pubmed: 25858596
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3597-603
pubmed: 16186339
J Ophthalmol. 2012;2012:594869
pubmed: 23326647
Am J Transplant. 2007 Sep;7(9):2082-9
pubmed: 17614980
Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1743-51
pubmed: 15161835
Prog Retin Eye Res. 2022 Mar;87:100987
pubmed: 34237411
Int J Mol Sci. 2022 May 23;23(10):
pubmed: 35628669
Nature. 2013 Apr 25;496(7446):461-8
pubmed: 23467089
Nat Protoc. 2021 Oct;16(10):4539-4563
pubmed: 34426708
Sci Rep. 2020 Aug 14;10(1):13841
pubmed: 32796906
Stem Cells. 2018 Dec;36(12):1851-1862
pubmed: 30270540
Leukemia. 2018 Jul;32(7):1529-1541
pubmed: 29654266
Gene Ther. 2011 Aug;18(8):778-87
pubmed: 21412281
Sci Adv. 2022 Apr;8(13):eabn1772
pubmed: 35353558